1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Drugs In Development, 2022, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 7 and 1 respectively.
Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Binge Eating Disorder - Overview
- Binge Eating Disorder - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Binge Eating Disorder - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Binge Eating Disorder - Companies Involved in Therapeutics Development
- Amygdala Neurosciences Inc
- AWAKN Life Sciences Corp
- Bioprojet SCR
- Bright Minds Biosciences Inc
- Chronos Therapeutics Ltd
- Clearmind Medicine Inc
- F. Hoffmann-La Roche Ltd
- Omeros Corp
- Otsuka Pharmaceutical Co Ltd
- OXonium Therapeutics
- Trigemina Inc
- Tryp Therapeutics Inc
- Yichang Renfu Pharmaceutical Co Ltd
- Binge Eating Disorder - Drug Profiles
- ANS-6637 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BP-1.4979 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- centanafadine SR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CMND-100 - Drug Profile
- Product Description
- Mechanism Of Action
- CT-010018 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CTDP-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
- Product Description
- Mechanism Of Action
- ketamine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lisdexamphetamine dimesylate - Drug Profile
- Product Description
- Mechanism Of Action
- OMS-527 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- oxytocin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- psilocybin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RO-5256390 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TRP-8803 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Binge Eating Disorder - Dormant Projects
- Binge Eating Disorder - Discontinued Products
- Binge Eating Disorder - Product Development Milestones
- Featured News & Press Releases
- Jun 29, 2022: Tryp Therapeutics strengthens IP portfolio with provisional patent application for binge eating disorder treatment
- Jun 09, 2022: Tryp Therapeutics announces results of first patient dosed in its phase II clinical trial for the treatment of binge eating disorder
- May 26, 2022: Awakn Life Sciences files Patent Cooperation Treaty (PCT) Application for the treatment of behavioral addictions
- May 10, 2022: SciSparc and Clearmind Medicine collaboration yields new patent application for psychedelic combination treatment for binge behaviors
- Apr 28, 2022: Tryp Therapeutics doses first patient in phase II psilocybin-assisted therapy clinical trial
- Mar 23, 2022: Tryp Therapeutics initiates enrollment for binge eating disorder study in partnership with University of Florida
- Jan 05, 2022: Awakn Life Sciences expands world’s first ketamine study beyond gambling disorder to include additional behavioral addictions
- Dec 23, 2021: Tryp Therapeutics announces advancement of phase 2a clinical trial in binge eating disorder
- Dec 03, 2021: Tryp Therapeutics to present at the H.C. Wainwright Psychedelics Conference on December 6, 2021
- Nov 18, 2021: Tryp Therapeutics provides update on clinical hold for phase 2a study for eating disorders
- Sep 22, 2021: Bright Minds Biosciences provides scientific update
- Mar 03, 2021: Bright Minds Biosciences (“BMB”) proprietary 5-HT2C agonists show significant reduction in binge eating
- May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder
- Oct 06, 2016: Study Finds New Approach to Block Binge Eating
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Binge Eating Disorder, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Binge Eating Disorder - Pipeline by Amygdala Neurosciences Inc, 2022
- Binge Eating Disorder - Pipeline by AWAKN Life Sciences Corp, 2022
- Binge Eating Disorder - Pipeline by Bioprojet SCR, 2022
- Binge Eating Disorder - Pipeline by Bright Minds Biosciences Inc, 2022
- Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, 2022
- Binge Eating Disorder - Pipeline by Clearmind Medicine Inc, 2022
- Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Binge Eating Disorder - Pipeline by Omeros Corp, 2022
- Binge Eating Disorder - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
- Binge Eating Disorder - Pipeline by OXonium Therapeutics, 2022
- Binge Eating Disorder - Pipeline by Trigemina Inc, 2022
- Binge Eating Disorder - Pipeline by Tryp Therapeutics Inc, 2022
- Binge Eating Disorder - Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2022
- Binge Eating Disorder - Dormant Projects, 2022
- Binge Eating Disorder - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Binge Eating Disorder, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amygdala Neurosciences Inc
- AWAKN Life Sciences Corp
- Bioprojet SCR
- Bright Minds Biosciences Inc
- Chronos Therapeutics Ltd
- Clearmind Medicine Inc
- F. Hoffmann-La Roche Ltd
- Omeros Corp
- Otsuka Pharmaceutical Co Ltd
- OXonium Therapeutics
- Trigemina Inc
- Tryp Therapeutics Inc
- Yichang Renfu Pharmaceutical Co Ltd
